aslan
pharmaceuticals
completes
enrolment
second
cohort
opens
new
sites
us
australia
atopic
dermatitis
study
singapore
globe
newswire
aslan
pharmaceuticals
nasdaq
asln
immunology
oncology
focused
biopharmaceutical
company
developing
innovative
treatments
transform
lives
patients
today
announced
clinical
sites
us
australia
open
ready
enrol
patients
multiple
ascending
dose
mad
study
testing
therapeutic
antibody
moderate
severe
atopic
dermatitis
ad
patients
patients
recruited
sites
australia
sites
us
alongside
existing
sites
singapore
aslan
recently
restarted
recruitment
second
cohort
randomised
double
blind
study
singapore
following
lifting
government
restrictions
response
patients
fully
recruited
cohort
aslan
plans
initiate
recruitment
third
cohort
following
approval
data
monitoring
committee
patients
recruited
singapore
us
australia
aslan
expects
report
interim
unblinded
data
dose
cohorts
dr
kenneth
kobayashi
chief
medical
officer
aslan
pharmaceuticals
said
speed
able
fully
recruit
second
cohort
mad
study
since
restrictions
lifted
singapore
last
month
reaffirms
scale
demand
patients
interest
physicians
innovative
treatments
ad
accelerated
plans
open
new
study
sites
us
australia
pleased
sites
ready
monoclonal
antibody
binds
receptor
subunit
blocking
signalling
two
cytokines
central
triggering
symptoms
ad
redness
itching
skin
ends
media
ir
contacts
emma
thompson
spurwing
communications
tel
email
aslan
robert
uhl
westwicke
partners
tel
email
aslan
pharmaceuticals
aslan
pharmaceuticals
nasdaq
asln
immunology
oncology
focused
biopharmaceutical
company
developing
innovative
treatments
transform
lives
patients
led
senior
management
team
extensive
experience
global
development
commercialisation
aslan
clinical
portfolio
comprised
monoclonal
therapy
developed
atopic
dermatitis
immunology
indications
small
molecule
inhibitor
targeting
oncology
aslan
partners
include
almirall
array
biopharma
squibb
csl
additional
information
please
visit
forward
looking
statements
release
contains
statements
statements
based
current
beliefs
expectations
management
aslan
pharmaceuticals
limited
affiliates
company
statements
may
include
limited
statements
regarding
company
business
strategy
company
plans
develop
commercialise
safety
efficacy
company
plans
expected
timing
respect
enrolment
clinical
trials
clinical
study
results
company
estimates
projections
statements
based
management
current
assumptions
expectations
future
events
trends
affect
may
affect
company
business
strategy
operations
financial
performance
inherently
involve
significant
known
unknown
risks
uncertainties
actual
results
timing
events
could
differ
materially
anticipated
statements
result
risks
uncertainties
include
without
limitation
risk
factors
described
company
securities
exchange
commission
filings
reports
commission
file
including
company
form
filed
securities
exchange
commission
sec
april
statements
statements
historical
fact
statements
words
believe
may
might
could
aim
estimate
continue
anticipate
intend
expect
plan
negative
terms
similar
expressions
convey
uncertainty
future
events
outcomes
intended
identify
estimates
projections
statements
estimates
projections
statements
speak
date
made
except
extent
required
law
company
undertakes
obligation
update
review
estimate
projection
statement
